In Vitro Efficacy of Antiviral Compounds against Enterovirus D68
In Vitro Efficacy of Antiviral Compounds against Enterovirus D68
复制标题
DOI：
10.1128/aac.00766-15
复制
发表时间：
2015-12-01
影响因子：
4.9
通讯作者：
Oberste, M. Steven
中科院分区：
文献类型：
--
作者：
Rhoden, Eric;Zhang, Mingyu;Oberste, M. Steven
2014年，美国经历了与肠道病毒D68(EV-D68)相关的严重呼吸道疾病的大爆发。我们使用一种均质的、基于细胞的测试来评估针对EV/鼻病毒感染或其他适应症开发的化合物的抗病毒活性。15种化合物中有3种对所有四种测试菌株(原型和三种2014年菌株)具有高度活性，50%有效浓度在0.0012至0.027亩M之间。还需要进一步研究，以评估它们对EV-D68的体内疗效。
In 2014, the United States experienced a large outbreak of severe respiratory illness associated with enterovirus D68 (EV-D68). We used a homogeneous, cell-based assay to assess the antiviral activity of compounds developed for EV/rhinovirus infection or other indications. Three of 15 compounds were highly active against all four strains tested (the prototype and three 2014 strains), with 50% effective concentrations of 0.0012 to 0.027 mu M. Additional studies are needed to assess their in vivo efficacy against EV-D68.